

eFigure 1. Crude association between the proportion of men discussed at multidisciplinary care planning (upper panel), regional patient volume (middle panel), regional population (lower panel), and the proportion of men with any added treatment.



eFigure 2. Proportion per region in Sweden of 3697 men with *de novo* mCSPC, who received added drug or local radiotherapy along with standard ADT (left panel) or added drug treatment along with standard ADT (right panel).



eFigure 3. Proportion per region in Sweden of 3697 men with *de novo* mCSPC, who received additional treatment with any of abiraterone, enzalutamide, or apalutamide (Abi/Enza/Apa: left panel), docetaxel (middle panel), or radiotherapy (right panel).

